Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy - PubMed
3 hours ago
- #Bladder cancer
- #EGFR
- #ROS
- Sanguinarine chloride (SANC) inhibits bladder cancer cell proliferation, colony formation, and migration.
- SANC binds to EGFR and downregulates the PI3K/AKT/FOXO3a signaling pathway, leading to cell cycle arrest and apoptosis.
- SANC increases ROS levels and depletes GSH, disrupting redox balance and suppressing EGFR activity.
- In vivo studies show SANC reduces tumor growth without significant toxicity.
- SANC is a promising novel EGFR-targeted therapy for bladder cancer.